The Contribution of GWAS Loci in Familial Dyslipidemias
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples. We also constructed weighted polygenic scores using 212 lipid-associated SNPs and estimated the relative contributions of Mendelian variants and polygenic scores to the risk of FCH in the families. We identified, across the whole allele frequency spectrum, an enrichment of variants known to elevate, and a deficiency of variants known to lower LDL-C and/or TG levels among both probands and affected FCH individuals. The score based on TG associated SNPs was particularly high among affected individuals compared to non-affected family members. Out of 234 affected FCH individuals across the families, seven (3%) carried Mendelian variants and 83 (35%) showed high accumulation of either known LDL-C or TG elevating variants by having either polygenic score over the 90th percentile in the population. The positive predictive value of high score was much higher for affected FCH individuals than for similar sporadic cases in the population. FCH is highly polygenic, supporting the hypothesis that variants across the whole allele frequency spectrum contribute to this complex familial trait. Polygenic SNP panels improve identification of individuals affected with FCH, but their clinical utility remains to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a novel, first-in-class, oral small molecule that inhibits cholesterol synthesis by inhibiting the action of ATP citrate lyase, a cytosolic enzyme upstream of 3-hydroxy-3-methylglutarylcoenzyme A reductase [340].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [340]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983 · cited 1×
“To construct a polygenic lipid score, we catalogued and used 212 SNPs, representing either the lead SNPs for genome-wide significant associations to LDL-C or TG from GWA studies of these traits (171 SNPs), or SNPs catalogued in the Online Mendelian Inheritance in Man (OMIM) database as located in genes implicated in p…”
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443 · cited 1×
“Familial combined hyperlipidemia (FCH), classically defined by elevations in serum total cholesterol (TC), triglycerides (TG), or both, in two or more first degree relatives, displays a prevalence of greater than 1% in Western populations [1, 2].”
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationFamilial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 596 · cited 1×
“It is the most common familial risk factor for premature coronary heart disease (CHD), occurring in 11–14% of individuals with this condition, and raising by up to five-fold the CHD risk in first- and second-degree relatives of affected individuals [3, 4].”
Talmud, P. J., Shah, S., Whittall, R., Futema, M., Howard, P., Cooper, J. A., Harrison, S. C., Li, K., Drenos, F., Karpe, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62127-8 · Cited by 591 · cited 1×
“This emphasizes the polygenic nature of FCH and is in line with previous results with familial hypercholesterolemia demonstrating that this less prevalent syndrome has a polygenic component [9].”
Talmud, P. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3039 · Cited by 365 · cited 1×
“APOA5 rs3135506, which predisposes to hypertriglyceridemia in homozygous form [12], was 1.”
The impact of low-frequency and rare variants on lipid levels
ENGAGE Consortium, Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3300 · Cited by 351
Self-citation
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“FCH has no monogenic component and is not linked to a single genetic cause, but the phenotype is high LDL-C and/or high TGs.(358,359) Therefore, the diagnosis is commonly missed in clinical practice; the combination of ApoB >120 mg/dL and TGs >1.”
Self-citationA decade of genome-wide association studies for coronary artery disease: the challenges ahead
Erdmann, J., Kessler, T., Munoz Venegas, L., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 325
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals
Natarajan, P., Peloso, G. M., Zekavat, S. M., Montasser, M., Ganna, A., Chaffin, M., Khera, A. V., Zhou, W., Bloom, J. M., Engreitz, J. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05747-8 · Cited by 183
Self-citationGenetic architecture of human plasma lipidome and its link to cardiovascular disease
Tabassum, R., Rämö, J. T., Ripatti, P., Koskela, J. T., Kurki, M., Karjalainen, J., Palta, P., Hassan, S., Nunez-Fontarnau, J., Kiiskinen, T. T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11954-8 · Cited by 175
Self-citationGeographic variation and bias in polygenic scores of complex diseases and traits in Finland
Kerminen, S., Martin, A. R., Koskela, J., Ruotsalainen, S. E., Havulinna, A. S., Surakka, I., Palotie, A., Perola, M., Salomaa, V., Daly, M. J., et al. (2018) · doi:10.1101/485441 · Cited by 115
“2017) and imputed genotypes as described in (Ripatti et al. 2016).”
BackgroundSelf-citationGeographic Variation and Bias in the Polygenic Scores of Complex Diseases and Traits in Finland
Kerminen, S., Martin, A. R., Koskela, J., Ruotsalainen, S. E., Havulinna, A. S., Surakka, I., Palotie, A., Perola, M., Salomaa, V., Daly, M. J., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.001 · Cited by 115
“For the genetic analyses, we used genotypes from Illumina HumanCoreExome-12 BeadChip (see details in Kerminen et al.13) and imputed genotypes as described by Ripatti et al.21 e 6, 2019”
MethodSelf-citationCommon Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families
Gormley, P., Kurki, M., Hiekkala, M. E., Veerapen, K., Häppölä, P., Mitchell, A. A., Lal, D., Palta, P., Surakka, I. L., Kaunisto, M. A., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.014 · Cited by 108
“Studies in familial dyslipidemias have shed some light on this, by demonstrating that both rare (penetrant) andcommon (lesspenetrant) variants havebeen associated to specific lipid traits (Khera et al., 2017a; Ripatti et al., 2016).”
Self-citationPolygenic Hyperlipidemias and Coronary Artery Disease Risk
Ripatti, P., Rämö, J. T., Mars, N. J., Fu, Y., Lin, J., Söderlund, S., Benner, C., Surakka, I., Kiiskinen, T., Havulinna, A. S., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002725 · Cited by 104
Self-citationDNA methylation in human lipid metabolism and related diseases
Mittelstraß, K., & Waldenberger, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000491 · Cited by 85
Familial Combined Hyperlipidemia: Current Knowledge, Perspectives, and Controversies
Bello-Chavolla, O. Y., Kuri-García, A., Ríos-Ríos, M., Vargas-Vázquez, A., Cortés-Arroyo, J. E., Tapia-González, G., Cruz-Bautista, I., & Aguilar-Salinas, C. A. (2018) · Revista de Investigación Clínica · doi:10.24875/ric.18002575 · Cited by 53
The Genetic Basis of Hypertriglyceridemia
Carrasquilla, G. D., Christiansen, M. R., & Kilpeläinen, T. O. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00939-y · Cited by 62
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia
Trinder, M., Vikulova, D. N., Pimstone, S. N., Mancini, G. B. J., & Brunham, L. R. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.032 · Cited by 50
Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia
Gill, P. K., Dron, J. S., Berberich, A. J., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.11.006 · Cited by 45
The Hong Kong Diabetes Register TRS Study Group, Tam, C. H. T., The Hong Kong Diabetes Biobank Study Group, Lim, C. K. P., Luk, A. O. Y., Ng, A. C. W., Lee, H. M., Jiang, G., Lau, E. S. H., Fan, B., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00831-z · Cited by 39
“viduals with similar lipid levels in the general population [41].”
BackgroundRämö, J. T., Ripatti, P., Tabassum, R., Söderlund, S., Matikainen, N., Gerl, M. J., Klose, C. D., Surma, M. A., Stitziel, N. O., Havulinna, A. S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012415 · Cited by 35
Self-citationSul, J. H., Service, S. K., Huang, A., Ramensky, V. E., Hwang, S., Teshiba, T. M., Park, Y., Ori, A. P. S., Zhang, Z., Mullins, N., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0758-1 · Cited by 37
Self-citationTaghizadeh, E., Mardani, R., Rostami, D., Taghizadeh, H., Bazireh, H., & Hayat, S. M. G. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28311 · Cited by 29
Effects of Apigenin on the Expression of LOX‐1, Bcl‐2, and Bax in Hyperlipidemia Rats
Xu, Q., Li, Y., Du, C., Wang, L., & Xiao, Y. (2021) · Chemistry & Biodiversity · doi:10.1002/cbdv.202100049 · Cited by 34
Familial combined hyperlipidemia is a polygenic trait
Gill, P. K., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000796 · Cited by 28
Hassan, S., Surakka, I. L., Taskinen, M., Salomaa, V. V., Palotie, A. V., Wessman, M., Tukiainen, T., Pirinen, M., Palta, P., & Ripatti, S. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00768-8 · Cited by 24
Self-citationMetabolic Syndrome: An Overview on Its Genetic Associations and Gene–Diet Interactions
Prone-Olazábal, D., Davies, I. G., & González-Galarza, F. F. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0125 · Cited by 20
“108,109 For example, the locus 1q21-23 has been associated with different lipid traits such as HTG, where the group of genes APOA1/C3/A4/A5 is related to the presence of FCS. 110 Similarly, the USF1 gene is re-lated to various target genes related to glucose and lipid metabolism.”
Lin, L., Kiryakos, J., Ammous, F., Ratliff, S. M., Ware, E. B., Faul, J. D., Kardia, S. L. R., Zhao, W., Birditt, K. S., & Smith, J. A. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01914-7 · Cited by 23
“Multiple risk factors are associated with the development of dyslipidemia, including behaviors such as unhealthy diet, lack of exercise [15], and genetic factors [16–19].”
BackgroundSaarentaus, E., Havulinna, A. S., Mars, N., Ahola‐Olli, A., Kiiskinen, T., Partanen, J., Ruotsalainen, S., Kurki, M., Urpa, L., Chen, L., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01026-z · Cited by 20
Self-citationSchlafly, A., Pfeiffer, R. M., Nagore, E., Puig, S., Calista, D., Ghiorzo, P., Menin, C., Fargnoli, M. C., Peris, K., Song, L., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008490 · Cited by 17
“High PRS has already been reported for families with migraines [6], dyslipidemia [7, 8], Crohn’s disease [9], Alzheimer’s [10], schizophrenia [11], and breast cancer with [12] and without [13–15] BRCA mutations.”
BackgroundHuman genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
ANGPTL3 gene variants in subjects with familial combined hyperlipidemia
Bea, A. M., Franco-Marín, E., Marco-Benedí, V., Jarauta, E., Gracia‐Rubio, I., Cenarro, A., Civeira, F., & Lamíquiz-Moneo, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-86384-y · Cited by 14
Lin, J., Tabassum, R., Ripatti, S., & Pirinen, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00431 · Cited by 13
“…biobank studies as well as in some disease specific collections have focused on, for example, Type 2 diabetes (T2D) (Mahajan et al., 2018) or coronary artery disease (CAD) (Ripatti et al., 2016), multiple related quantitative traits are simultaneously available for genetic association studies.”
BackgroundSelf-citationApproach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Genetic risk scores in lipid disorders
Wierzbicki, A. S., & Reynolds, T. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000623 · Cited by 10
“The most recent started with 53 Finnish families (average size 13 members) containing 234 affected individuals in a cohort of 715 patients [56].”
BackgroundGenome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update
Taghizadeh, E., Farahani, N., Mardani, R., Taheri, F., Taghizadeh, H., & Hayat, S. M. G. (2021) · Biochemical Genetics · doi:10.1007/s10528-021-10130-2 · Cited by 8
Familial Combined Hyperlipidemia: Myth or Reality?
Brouwers, M. C. G. J., Klop, B., Ribalta, J., & Cabezas, M. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01289-9 · Cited by 6
“…the clinical characteristics of the included subjects or to the selection of the SNPs included in the PRS, they coincide in that approximately 25% of FCHL individuals show an over-representation of triglyceride-raising SNPs, whereas the presence of SNPs raising LDL-C seems clearly lower [52, 53].”
Zaher, N. H., Rashed, E. R., & El‐Ghazaly, M. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0054 · Cited by 6
Cardiero, G., Ferrandino, M., Calcaterra, I. L., Iannuzzo, G., Minno, M. N. D. D., Buganza, R., Guardamagna, O., Auricchio, R., Taranto, M. D. D., & Fortunato, G. (2024) · Genes · doi:10.3390/genes15040462 · Cited by 7
“FCH is a polygenic disease in which different SNPs have been implicated for their association with LDL-c and triglyceride levels [47,48].”
BackgroundBielicki, P., Pływaczewski, R., Brzóska, K., Kumor, M., Barnaś, M., Jończak, L., Stępkowski, T. M., Piechuta, A., Chazan, R., Śliwiński, P., et al. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4406 · Cited by 9
Wei, A., Border, R., Fu, B., Cullina, S., Brandes, N., Jang, S.-K., Sankararaman, S., Kenny, E. E., Udler, M. S., Ntranos, V., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60339-7 · Cited by 6
Exome risk score for predicting susceptibility to and severity of isolated thoracic aortic aneurysm
Li, Y., Song, L., Rong, W., Zhang, Y., Yao, X., Fang, X., Li, Y., & Du, J. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac099 · Cited by 3
Carmena, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65333-3 · Cited by 3
CORONARY ARTERY DISEASE RISK AND LIPIDOMIC PROFILES IN FAMILIAL HYPERLIPIDEMIAS
Rämö, J. T., Ripatti, P., Tabassum, R., Söderlund, S., Matikainen, N., Gerl, M. J., Klose, C. D., Surma, M. A., Stitziel, N. O., Havulinna, A. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(19)32376-9 · Cited by 2
Self-citationMelnik, B. C. (2022) · Springer eBooks · doi:10.1007/978-3-662-63709-8_89 · Cited by 2
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 2
Melnik, B. C. (2020) · Springer eBooks · doi:10.1007/978-3-662-58713-3_89-1
Living Between Sickness and Health: Where Is the Human Genome Leading Us?
Broadwater, A., & Pathak, Y. V. (2018) · Springer eBooks · doi:10.1007/978-981-10-7506-3_2
Ultrassequenciamento exômico dos principais genes relacionados com a hipercolesterolemia familial
Borges, J. B. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2019.tde-29032019-103233 · Cited by 1
Lipid Disorders: Advances in Research and Challenges in Clinical Practice
Aguilar-Salinas, C. A., Tussié-Luna, T., & Almeda‐Valdés, P. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.m18000001
Чернышов, В. А. (2021) · Ukrainian Therapeutical Journal · doi:10.30978/utj2021-2-47
Melnik, B. C. (2018) · Springer eBooks · doi:10.1007/978-3-662-49544-5_89
Melnik, B. C. (2016) · Springer eBooks · doi:10.1007/978-3-662-49546-9_89-1
Tam, C. H. T., Lim, C. K. P., Luk, A. O. Y., Ng, A. C. W., Lee, H. M., Jiang, G., Lau, E. S. H., Fan, B., Wan, R., Kong, A. P. S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14068007
Familial combined hyperlipidemia: current status of the problem (literature review)
Тимощенко, О. В., & Шахтшнейдер, Е. В. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5874
Jannatalipour, A., Bioky, A. A., Tavasoli, N., Farsi, F., Bidkhori, M., Sehatpour, F., Soltani, A., Ostovar, A., Nabipour, I., Fahimfar, N., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01720-7
Tam, C. H. T., Lim, C. K. P., Luk, A. O. Y., Ng, A. C. W., Lee, H.-M., Jiang, G., Lau, E. S. H., Fan, B., Wan, R., Kong, A. P.-S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14068004
Lin, L., Kiryakos, J., Ammous, F., Ratliff, S. M., Ware, E. B., Faul, J. D., Kardia, S. L. R., Zhao, W., Birditt, K. S., & Smith, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.25910051
Vitamine A & vitamine D : impact global sur l'inflammation adipocytaire associée à l'obésité
Karkeni, E. (2016) · theses.fr (ABES) · doi:10.70675/bcce8634zb6c2z4aa6z8087z28105ca495f1
Bonnet, L. (2017) · theses.fr (ABES) · doi:10.70675/d064f8b7z2b50z4dfdz943azc64473c5a735 · Cited by 1
Rare variants in cholesterol transporter genes in patients with lipid metabolism disorders
Izyumchenko, A. D., Грунина, М. Н., Dracheva, K. V., Chumakova, O. A., Tanayants, K. O., Legostaeva, K. V., Kulikov, A. N., Berkovich, O. A., Baranova, E. I., Pchelina, S. N., et al. (2026) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-26-53
Bararu‐Bojan, I., Vladeanu, M. C., Iliescu-Halițchi, D., Pleșoianu, C. E., Bojan, A., Frăsinariu, O. E., Tudor, R. C., Ciocoiu, M., Tudor, C., Haliţchi, C. I., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16152313
Metadata
- Authors
- Ripatti, P., Rämö, J. T., Söderlund, S., Surakka, I., Matikainen, N., Pirinen, M., Pajukanta, P., Sarin, A.-P., Service, S. K., Laurila, P.-P., Ehnholm, C., Salomaa, V., Wilson, R. K., Palotie, A., Freimer, N. B., Taskinen, M.-R., & Ripatti, S.
- Affiliations
- University of Helsinki (FI)
- Broad Institute (US)
- University of California, Los Angeles (US)
- Finnish Institute for Health and Welfare (FI)
- Washington University in St. Louis (US)
- Corresponding author
- Ripatti, Samuli
- ORCID
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-26
- Volume
- 12
- Issue
- 5
- Pages
- e1006078
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC4882070
- OpenAlex
- W2289474097
- Cited by
- 60
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 1 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 10 · 2018: 10 · 2017: 4 · 2016: 2
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- National Institutes of Health (HL113315, HL095056, HL28481)
- Sydäntutkimussäätiö
- Sigrid Juséliuksen Säätiö
- Biocentrum Helsinki
- EU 7th Framework Program (305707)
- Helsinki University Central Hospital Fund
- University of Helsinki Jubilee Fund
- Helsingin Yliopisto
- Suomen Lääketieteen Säätiö
- Emil Aaltosen Säätiö
- Biomedicum Helsinki-säätiö
- Suomen Akatemia (251217)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- familial combined hyperlipidemia, familial dyslipidemia, polygenic risk score, allele frequency spectrum, triglycerides, LDL cholesterol, genetic architecture, coronary heart disease risk, Finnish families
- MeSH terms
- Adult, Apolipoproteins B, Coronary Artery Disease, Female, Humans, Hyperlipidemia, Familial Combined, Cholesterol, HDL, Lipoproteins, LDL, Male, Middle Aged, Triglycerides, Dyslipidemias, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.